Beth Herskovits

Biotech takes issue with move to limit reimbursement.

Restasis goes against the grain of Rx-to-OTC switching.

Drug makers find it hard to recoup development costs, report finds.

Active Care Network and biotech partners aim to increase patient compliance.

Schwarz's Neupro is company's first new chemical entity launched in US.

Beneficiaries don't switch back to brands after trying generics.

Provenge setback not deterring others in the field.

'Very hostile' FDA panel recommends tighter prescribing guidelines.

High settlement could suggest frustration with pharma's marketing tactics.